INTRODUCTION
Acute promyelocytic leukemia (APL) is characterized by a clonal expansion of myeloid precursor cells blocked at promyelocyte. In over 95 % of APL patients, reciprocal chromosomal translocation t (15; 17) fuses the promyelocytic leukemia (PML) gene to the retinoic acid receptor (RAR) gene, yielding the fusion protein PML/RAR . 1, 2 PML is a ubiquitously expressed nuclear protein containing the RING domain, B1
and B2 boxes and -helical coiled-coil domain 3, 4 . PML forms a homodimer and localizes in the speckled subnuclear structure referred to as nuclear bodies (NBs) 5 ,
where it interacts with various proteins including p53 and retinoblastoma protein and modifies their functions. [6] [7] [8] [9] PML -/-mice were more feasible to develop lymphomas than PML +/+ mice when challenged with mutagens, suggesting a possible role for PML as a tumor suppressor. 10, 11 In APL cells, PML/RAR delocalizes PML from NBs through the direct interaction and inhibits tumor-suppressive activity of PML, which is considered to play some role in leukemogenesis of APL. [12] [13] [14] The growth, differentiation and survival of myeloid cells are pivotally regulated by granulocyte colony-stimulating factor (G-CSF). After binding to the receptor, G-CSF activates Janus family tyrosine kinases (JAKs). The activated JAKs, in turn, induce phosphorylation and dimerization of signal transducers and activators of transcription (STATs), which translocate into the nucleus and initiate gene transcription. [15] [16] [17] [18] Although G-CSF activates STAT1, STAT3 and STAT5, STAT3 was shown to be essential for G-CSF-dependent proliferation and differentiation of myeloid cells. 19, 20 Considering the fact that STAT3 is a crucial regulator of development of myeloid
For personal use only. on . by guest www.bloodjournal.org From -4 -cells, we speculated that STAT3 activity might be dysregulated in APL cells. Here, we found that PML bound to STAT3 and inhibited its activity, which was cancelled by PML/RAR . Furthermore, PML abrogated STAT3-dependent growth of Ba/F3 cells, while it was enhanced by PML/RAR . These results suggest that PML/RAR could participate in the pathogenesis of APL through the dysregulation of STAT3 activity.
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MATERIALS& METHODS

Reagents and Antibodies
A rabbit anti-STAT3 antibody (Ab) (K-15), a goat anti-PML Ab (N-19) and normal rabbit IgG (control IgG) were purchased from Santa Cruz Biotechnology Inc (California, CA). A rhodamine-conjugated murine anti-goat IgG Ab and an FITC-conjugated murine anti-rabbit IgG Ab were purchased from Chemicon International Inc (Temecula, CA).
Plasmid constructs and cDNAs
Expression vectors for PML3 and PML/RAR were provided from Dr. M. Alcaley. 6 Flag-tagged PML mutants were generated by PCR and subcloned into pcDNA3 (Invitrogen, De Schelp, Netherlands)). Glutathione S-transferase (GST)-STAT3 constructs were generated by subcloning PCR products into pGEX-4T-1 (Pharmacia, Uppsala, Sweden). An expression vector for constitutively active STAT5A
(1*6-STAT5A) was provided by Dr. T. Kitamura (Tokyo University, Tokyo, Japan).
pEF-BOS-G-CSF-R/gp130 is an expression vector for G-CSF-R/gp130, a chimeric receptor composed of the extracellular domain of G-CSF receptor and cytoplasmic domain of gp130.
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Cell lines and cultures
293T, HepG2 and NIH3T3 cells were maintained in DMEM containing 10% fetal bovine serum (FBS). Murine IL-3-dependent cell lines, Ba/F3 and 32D, were cultured with RPMI1640 containing 10% FBS and 1 ng/mL of IL-3. To stably express PML and PML/RAR in Ba/F3, we transfected each expression vector by electroporation (250 V, For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -6 -960 µFD) (Bio-Rad Laboratories, Richmond, CA). The transfected cells were screened by the culture with G418 (1.5 mg/ml; Sigma, St Louis, MO). After the selection, we examined the expression levels of the transgene among the stable transformants by Western blot analysis. According to this result, 5 clones, in which each transgene was efficiently expressed, were selected and subjected to further analyses. 
Cell proliferation assays
Northern blot analysis
Northern blot analysis was performed as described previously.
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Immunoprecipitation and immunoblotting
293T cells were transfected with various expression vectors and pEF-BOS-G-CSF-R/gp130 by the calcium phosphate precipitation. After 32 h, the cells were stimulated with 30 ng/mL of G-CSF for 30 min and total cellular lysates were prepared as described previously. 23 The procedures for immunoprecipitation and immunoblotting were described previously.
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Electrophoretic mobility shift assay (EMSA)
The isolation of nuclear extracts and EMSA were performed as described previously. 23 The sequence of the probe to detect DNA-binding of STAT3 is based on the IL-6/IFN 
Luciferase assays
Luciferase assays were performed in NIH3T3, 293T, and HepG2 cells according to the methods described previously. 23 The details of the reporter genes for STAT3
(4×APRE-Luc containing the APRE sequence from the rat 2-microglobulin promoter), STAT5 (3× -Cas-Luc containing the GAS sequence from the bovine -casein promoter)
and STAT1 (4×ISRE-Luc containing the ISRE sequence from the murine GBP promoter) were described in the previous papers. 24, 25 The cells were transfected with various expression vectors along with 1 µg of an appropriate reporter gene and 10 ng of pRL-TK, an expression vector for Renilla luciferase. After 8 h, the cells were washed, incubated without serum for 24 h, and then cultured with or without an appropriate cytokine indicated (30 ng/mL of IL-6, 30 ng/mL of IFN , 5 U/mL of EPO or 30 ng/mL of G-CSF) for 6 h. We performed luciferase assays in 32D cells by electroporation as described previously. 23 Relative luciferase activity was calculated by normalizing transfection efficiency according to Renilla luciferase activity. The experiments were performed in triplicate, and similar results were obtained from at least four independent experiments.
GST-pulldown assays
GST-STAT3 fusion proteins expressed in Escherichia coli were purified on glutathione-Sepharose 4B beads (Pharmacia Next, we examined the in vitro binding between PML and several GST-STAT3 fusion proteins (Figure 2A ). Since we could not obtain the GST fusion protein containing full-length STAT3 as a soluble protein due to the formation of the inclusion body, we
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -10 -performed GST-pulldown experiments using GST-STAT3 each containing the truncated fragment of STAT3. At first, we examined the quality and quantity of fusion proteins by the Coomassie brilliant blue staining ( Figure 2B , lower panel), and found that purified GST-STAT3 (320-590) partially includes the degraded product (indicated by an arrow).
However, we could not prevent this degradation in spite of the repeated experiments.
Next, we examined which fusion protein binds to 35 S-labeled PML. As shown in Figure   2B , upper panel, PML bound to GST-STAT3 (107-377) and also, to a lesser degree, to GST-STAT3 (320-590). In contrast, PML scarcely bound to GST alone, GST-STAT3
(1-154) and GST-STAT3 (580-770). These results imply that STAT3 may bind to PML through the domain spanning amino acids 320-377. However, since GST-STAT3 PML showed no effect on the DNA-binding activity of IFN -activated STAT1 or EPO-activated STAT5 (data not shown), again suggesting that PML would specifically inhibit STAT3 activity.
Next, we examined the in vitro binding between GST-STAT3 (107-377) and several
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From -11 -PML mutants ( Figure 3A) . A mutant lacking the RING domain ( R) still bound to GST-STAT3 (107-377), whereas its affinity was lower than that of FL-PML. In contrast, RBB, RBBCC and RBBCC scarcely bound to GST -STAT3 (107-377) ( Figure 3B ).
The similar results were obtained from GST-STAT3 (320-590) (data not shown).
Consistent with the data on the in vitro binding, R repressed STAT3 activity as efficiently as FL-PML, whereas RBB, RBBCC and RBBCC showed little effect on STAT3 activity ( Figure 3C ). These results suggest that PML directly binds to STAT3 and inhibits its activity through B-box zinc finger and carboxyl-terminal domains.
PML/RAR restored STAT3 activity inhibited by PML.
Next, we examined whether PML/RAR interacts with STAT3 in 293T cells. In contrast to PML ( Figure 4A , lane 1), PML/RAR was not coimmunoprecipitated with STAT3 regardless of the treatment with all-trans retinoic acid ( Figure 4A, lanes 2 and 3) .
However, cotransfected PML/RAR dose-dependently inhibited the in vivo binding between PML and STAT3 ( Figure 4B ). In addition, PML/RAR canceled the inhibitory effects of PML on STAT3 activity and augmented IL-6-induced 4×APRE-Luc activity up to 33-fold in NIH3T3 cells ( Figure 4C ). Together, these results suggest that PML/RAR dissociates PML from STAT3 and cancels its inhibitory effects on STAT3 activity. To further provide insight into the effects of PML and PML/RAR on STAT3 activity, we performed the similar analysis with 293T cells, in which endogenous PML was hardly detectable by Western blotting (Figure 1) . As was the case with NIH3T3 cells, PML/RAR restored gp130-mediated STAT3 activity suppressed by PML ( Figure   4D ). When PML/RAR was transfected alone, PML/RAR stimulated 4×APRE-Luc activity up to 4-fold even without G-CSF stimulation. Since PML/RAR did not 
STAT3-dependent growth of Ba/F3 cells was inhibited by PML and enhanced by PML/RAR .
To assess the biologic significance of the interaction among PML, PML/RAR and STAT3, we transfected PML, PML/RAR and Mock (an empty expression vector) into IL-3-dependent Ba/F3 cells expressing G-CSF-R/gp130, in which gp130-mediated growth is essentially dependent on STAT3 activity. 21 At first, we screened the expression levels of each transgene and selected 5 single cell clones from the respective transfectants, in which PML or PML/RAR was expressed efficiently (the expression levels of PML and PML/RAR in each representative clone is shown in Figure 6A ).
When these clones were stimulated with G-CSF, the induction of STAT3-responsive genes, tis11 and junB, was reduced in PML-transfected clones as compared with that in PML/RAR -transfected clones (the data obtained from a representative clone is shown in Figure 6B ). Figure 6H ). In addition, the PML/RAR -transfected clone was still able to proliferate in response to 0.1 ng/mL of G-CSF, whereas the Mock-transfected clone hardly proliferated ( Figure   6I ). These data indicate that STAT3-dependent growth of Ba/F3 cells is inhibited by PML, while it is augmented by PML/RAR . In spite of the marginal effect of PML on STAT3-dependent gene expression, PML completely abrogated gp130-mediated proliferation in Ba/F3 cells. As for this reason, we speculated that cyclin-dependent kinase activities regulated by STAT3 might be abrogated by a partial loss of its target genes such as c-myc and cyclin D1. 16 21 For
DISCUSSION
We demonstrated here that STAT3 activity is inhibited by PML and augmented by PML/RAR . As for this mechanism, we found that PML directly bound to STAT3 in NBs, and thereby inhibited the DNA-binding activity of STAT3. In contrast, PML/RAR did not associate with STAT3, but inhibited the binding between PML and STAT3, probably through the heterodimerization with PML. In the present study, GST-pulldown assays revealed that STAT3 binds to the B-box and C-terminal domains of PML. Based on the previous report that PML/RAR and PML form a complex through the respective coiled-coil domains 12 , it seems to be strange that PML/RAR inhibits the binding between PML and STAT3. However, considering the fact that the PML oligomer is able to form NBs through the B-box domain 26 , while the PML-PML/RAR heterodimer lacks this ability, the structure of the B-box domain in the PML-PML/RAR heterodimer was supposed be somewhat different from that in the PML oligomer. Therefore, as a probable interpretation of this result, it was speculated that, if PML more preferentially binds to PML/RAR than STAT3, STAT3 might not be capable of binding to the PML-PML/RAR heterodimer any more due to the conformational change of the B-box domain. Taken together, our results suggest that PML/RAR would enhance STAT3 activity by reducing inhibitory effects of PML.
However, we also found that PML/RAR augmented gp130-mediated STAT3 activity in 293T cells even in the absence of PML. Therefore, it was speculated PML/RAR by itself could enhance STAT3 activity independently of PML through as yet undetermined mechanism. Because STAT3 activity is modulated by various binding molecules such as Smad1, c-Jun and p300 [27] [28] [29] , further studies focusing on the effects of PML/RAR on STAT3 is activated by various growth factors such as G-CSF, IL-6 and OSM in hematopoietic cells. Activated STAT3 regulates cytokine-dependent growth of hematopoietic cells by promoting G1/S progression through the induction of c-myc and cyclin D1. 16 21 In addition to the function in normal hematopoiesis, STAT3 was aberrantly activated in peripheral blood samples obtained from the patients with acute myeloid leukemia, lymphoblastic leukemia and polycytemia vera. 17 
